1. Hortsmann, RD, et al. Antiphagocytic activity of streptococcal M protein: selective binding of complement control protein factor H. Proceedings of the National Academy of Sciences USA 1988; 85: 1657–1661.
2. Fischetti, VA. Streptococcal M protein: molecular design and biological behavior. Clinical Microbiology Reviews 1989; 2: 285–300.
3. Beall, B, Facklam, R, Thompson, T. Sequencing emm-specific PCR products for routine and accurate typing of group A streptococci. Journal of Clinical Microbiology 1996; 34: 953–958.
4. Shimizu, Y, et al. Case report of toxic shock-like syndrome due to group A streptococcal infection [in Japanese]. Kansenshogaku Zasshi 1993; 67: 236–239.
5. Ikebe, T, et al. Changing prevalent T serotypes and emm genotypes of Streptococcus pyogenes isolates from streptococcal toxic shock-like syndrome (TSLS) patients in Japan. Epidemiology and Infection 2003; 130: 569–572.
6. Working Group on Severe Streptococcal Infections. Defining the group A streptococcal toxic shock syndrome. Journal of the American Medical Association 1993; 269: 390–391.
7. McNeil, SA, et al. Safety and immunogenicity of 26-valent group A Streptococcus vaccine in healthy adult volunteers. Clinical Infectious Diseases 2005; 41: 1114–1122.